Advertisement

Diabetes as a Determinant of Mortality in Cystic Fibrosis

  1. Parinya Chamnan, MD, MPH1,
  2. Brian SF Shine, MD, MS2,
  3. Charles S Haworth, MD3,
  4. Diana Bilton, MD4 and
  5. Amanda I Adler, MD, PhD (amanda.adler{at}addenbrookes.nhs.uk)1,3,5
  1. 1. MRC Epidemiology Unit, Institute of Metabolic Science, Cambridge
  2. 2. John Radcliffe Hospital, Oxford, UK
  3. 3. Adult CF Centre, Papworth Hospital, Cambridge, UK
  4. 4. Adult CF Clinic, Royal Brompton Hospital, London, UK
  5. 5. Wolfson Diabetes and Endocrine Clinic, Addenbrooke's Hospital, Cambridge, UK

    Abstract

    Background: Diabetes is increasingly common in cystic fibrosis (CF), but little exists describing its influence on mortality. Using national UK data, this study documents diabetes-specific mortality rates, estimates the impact of diabetes on survival, and estimates population attributable fractions.

    Methods: This retrospective cohort study identified 8,029 individuals aged 0–65 years from the UK CF Registry (1996–2005). 5,892 patients were included in analyses of mortality rates and 4,234 in analyses of risk factors. We calculated age-adjusted mortality rates using Poisson regression, standardized mortality ratios using the population of England and Wales, and relative risks using proportional hazards modeling.

    Findings: During 17,672 person-years of follow-up, 393 subjects died. The age-adjusted mortality rate was 1.8/100 person-years (95% CI 1.6 to 2.0). The age-adjusted mortality rates per 100 person-years were 2.0 (CI 1.8 to 2.4) in women and 1.6 (95% CI 1.4 to 1.9) in males, and 4.2 (95% CI 3.4–5.1) in individuals with diabetes vs 1.5 (95% CI 1.3 to 1.7) in those without diabetes. Independent risk factors for death included diabetes (hazard ratio, 95% confidence interval, 1.31 (1.03 to 1.67), female sex (1.71, 1.36 to 2.14) plus poorer pulmonary function, lower body mass index, B. cepacia infection, absence of S. aureus infection, allergic bronchopulmonary aspergillosis, liver disease, prior organ transplantation, and corticosteroid use.

    Interpretation: Individuals with CF die earlier with diabetes, which, if delayed or better treated, might reasonably extend survival, and merits testing.

    Footnotes

      • Received July 2, 2009.
      • Accepted November 2, 2009.

    This Article

    1. Diabetes Care November 16, 2009
    1. Online-Only Appendix
    2. All Versions of this Article:
      1. dc09-1215v1
      2. 33/2/311 most recent
    Advertisement